(NASDAQ: PRTA) Prothena Public Co's forecast annual revenue growth rate of 148.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Prothena Public Co's revenue in 2025 is $10,341,000.On average, 5 Wall Street analysts forecast PRTA's revenue for 2025 to be $1,677,880,539, with the lowest PRTA revenue forecast at $150,723,950, and the highest PRTA revenue forecast at $4,427,516,020. On average, 3 Wall Street analysts forecast PRTA's revenue for 2026 to be $9,421,108,130, with the lowest PRTA revenue forecast at $3,768,098,740, and the highest PRTA revenue forecast at $13,726,645,410.
In 2027, PRTA is forecast to generate $5,786,723,065 in revenue, with the lowest revenue forecast at $5,382,998,200 and the highest revenue forecast at $6,190,447,930.